Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered question first ministerially corrected answering member label previous answer version answering member constituency answering member constituency answering member printed answering member printed answering member label answering member label
tabling member	label

Search

1539101

registered interest
date	03/11/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diamorphine
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if his Department will take steps to increase the provision of Diamorphine Assisted Treatment.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	78838
answer	answer is ministerial correction date of answer 08/11/2022 answer text <p>Heroin Assisted Treatment (HAT) or Diamorphine Assisted Treatment (DAT) is a clinical intervention supported by the 2017 United Kingdom-wide drug treatment guidelines. Local authorities in England are responsible for commissioning drug treatment services, including whether to commission HAT services within its resources for drug treatment funding. The Government supports areas which pursue HAT, where the relevant licences are obtained from the Home Office and in 2021, the former Public Health England provided additional guidance on commissioning and developing a HAT service.</p><p>The 10-year drug strategy is supported by £780 million, including £532 million for local authorities to invest in treatment and recovery services, in addition to the Public Health Grant. This allows local authorities to determine which interventions will complement existing treatments. The Office for Health Improvement and Disparities provides oversight of local delivery and monitors implementation against the aims of the drug strategy.</p> answering member constituency Harborough answering member printed Neil O'Brien question first answered 08/11/2022 17:24:04 answering member 4679 label Biography information for Neil O'Brien
tabling member	4769 label Biography information for Daisy Cooper

1538620

registered interest
date	02/11/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to increase the number of independent qualified prescribers in community pharmacies.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	77618
answer	answer is ministerial correction date of answer 08/11/2022 answer text <p>From 2026, all pharmacists will qualify with a prescribing qualification. We are also training approximately 3,000 pharmacists to be independent prescribers in each year until 2024. This training is accessible to pharmacists in all settings including community pharmacy, general practice and hospitals. In addition, independent prescribing pilots will commence England from 2023 to test how National Health Service clinical services with a prescribing element could be introduced in community pharmacy in England.</p> answering member constituency Harborough answering member printed Neil O'Brien question first answered 08/11/2022 17:15:58 answering member 4679 label Biography information for Neil O'Brien
tabling member	4769 label Biography information for Daisy Cooper

1538642

registered interest
date	02/11/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	General Practitioners: Negligence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether the Clinical Negligence Scheme for General Practice covers GPs for (a) telephone consultations and (b) advice given to patients who are temporarily abroad on holiday.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	77619
answer	answer is ministerial correction date of answer 08/11/2022 answer text <p>The Clinical Negligence Scheme for General Practice (CNSGP) is a state clinical negligence scheme in England which covers activities delivered under relevant contracts specified in regulations. Both telephone consultations and advice to patients abroad are covered by what is defined as a ‘relevant function’ in the Scheme’s rules and regulations. Both would therefore be covered by the CNSGP, as long as the patient is registered in England. In the case of advice to patients abroad, the general practitioner would provide services through the health service in England.</p> answering member constituency Harborough answering member printed Neil O'Brien question first answered 08/11/2022 17:17:27 answering member 4679 label Biography information for Neil O'Brien
tabling member	4769 label Biography information for Daisy Cooper

1537499

registered interest
date	31/10/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Tixagevimab/cilgavimab: USA
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether her Department has had discussions with the Centre for Disease Control in the US on their use of Evusheld as a pre-exposure prophylaxis to prevent Covid-19 in people who are moderately to severely immunocompromised.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	74934
answer	answer is ministerial correction date of answer 08/11/2022 answer text <p>The Antivirals and Therapeutics Taskforce has regular engagement with international partners to share learning on the use, deployment and evaluation of therapeutics and antivirals, including Evusheld. The Taskforce recently met with counterparts from the United States of America and discussed the recent change to the Food and Drug Administration’s treatment guidelines, which recommends physicians advise individuals to have appropriate alternate treatment plans in place, should emerging COVID-19 variants be resistant to Evusheld.</p><p>We continue monitoring whether and how other countries are using pre-exposure prophylactic treatments in people who are moderately to severely immunocompromised.</p> answering member constituency Colchester answering member printed Will Quince question first answered 08/11/2022 15:42:46 answering member 4423 label Biography information for Will Quince
tabling member	4769 label Biography information for Daisy Cooper

1537500

registered interest
date	31/10/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has made any preparations to introduce antibody testing before Christmas 2022 for immunocompromised and immunosuppressed patients who may not mount a full response to Covid vaccines.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	74935
answer	answer is ministerial correction date of answer 04/11/2022 answer text <p>The Antivirals and Therapeutics Taskforce is exploring options for a pilot study to test antibody levels in immunosuppressed patients to provide clinical evidence of a potential protective vaccine response. This could inform a wider testing programme identifying those who have mounted a protective antibody response following vaccination and provide more informed advice.</p><p>No specific cost estimate has yet been made. However, officials are in discussions with experts in this area and further information will be available in due course.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 74936 question first answered 04/11/2022 13:25:49 answering member 4423 label Biography information for Will Quince
tabling member	4769 label Biography information for Daisy Cooper

1537501

registered interest
date	31/10/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the cost of providing antibody testing to the estimated 500,000 immunocompromised and immunosuppressed patients who may not mount a full response to the covid-19 vaccines.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	74936
answer	answer is ministerial correction date of answer 04/11/2022 answer text <p>The Antivirals and Therapeutics Taskforce is exploring options for a pilot study to test antibody levels in immunosuppressed patients to provide clinical evidence of a potential protective vaccine response. This could inform a wider testing programme identifying those who have mounted a protective antibody response following vaccination and provide more informed advice.</p><p>No specific cost estimate has yet been made. However, officials are in discussions with experts in this area and further information will be available in due course.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 74935 question first answered 04/11/2022 13:25:49 answering member 4423 label Biography information for Will Quince
tabling member	4769 label Biography information for Daisy Cooper

1537506

registered interest
date	31/10/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Members: Correspondence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 28 October 2022 to Question 66030 on Members: Correspondence, notwithstanding the two replies received on 16 August 2022 to the letter of 20 December 2021, reference DC21853, and to the letter of 13 April 2022, reference DC24111, both relating to ambulance waiting times, when he plans to respond to the letter originally sent on 13 May 2022, and subsequently resent on 21 July, 10 August, 7 September, 29 September and 17 October, reference DC5119, relating to the investigation of allegations of historical sexual abuse in the NHS.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	74937
answer	answer is ministerial correction date of answer 08/11/2022 answer text <p>The former Parliamentary Under Secretary of State (James Morris MP) replied to the hon. Member on 16 August 2022. I will write to the hon. Member shortly.</p> answering member constituency Colchester answering member printed Will Quince question first answered 08/11/2022 17:41:08 answering member 4423 label Biography information for Will Quince previous answer version 31100 answering member constituency Colchester answering member printed Will Quince answering member 4423 label Biography information for Will Quince
tabling member	4769 label Biography information for Daisy Cooper

1535553

registered interest
date	24/10/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Palivizumab
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 September to Question 47662, whether a specific date has been confirmed for NHS England’s Palivizumab National Expert Group to report its recommendations to the JCVI.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	69808
answer	answer is ministerial correction date of answer 02/11/2022 answer text <p>The Palivizumab National Expert Group has now reported the outcome of its discussion and recommendations to the Joint Committee on Vaccination Immunisation, which will be discussed in a forthcoming meeting. A specific date has for this meeting has not yet been confirmed.</p> answering member constituency Harborough answering member printed Neil O'Brien question first answered 02/11/2022 11:49:11 answering member 4679 label Biography information for Neil O'Brien
tabling member	4769 label Biography information for Daisy Cooper

1524046

registered interest
date	19/10/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Tixagevimab/cilgavimab
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has (a) sought and (b) received advice from immunologists on the effectiveness of Evusheld.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	67224
answer	answer is ministerial correction date of answer 01/11/2022 answer text <p>The Government’s decision not to procure Evusheld at this time was based on independent clinical advice by the multi-agency RAPID C-19 <del class="ministerial">and a United Kingdom national expert policy working group. RAPID C-19</del> <ins class="ministerial">. </ins><ins class="ministerial">DHSC also </ins>sought advice from <del class="ministerial">the</del> <ins class="ministerial">a United Kingdom national </ins>expert <ins class="ministerial">policy </ins>working group, which includes a range of expertise including immunology, virology and relevant specialisms such as oncology. The membership of these groups also included experts in interpreting and analysing complex data, including clinicians and pharmacists, evidence assessors, and researchers.</p> answering member constituency Colchester answering member printed Will Quince previous answer version 26776 answering member constituency Newark answering member printed Robert Jenrick answering member 4320 label Biography information for Robert Jenrick 29371 answering member constituency Colchester answering member printed Will Quince answering member 4423 label Biography information for Will Quince question first answered 01/11/2022 12:26:19 question first ministerially corrected 21/02/2023 14:40:12 answering member 4423 label Biography information for Will Quince
tabling member	4769 label Biography information for Daisy Cooper

1523425

registered interest
date	18/10/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Tixagevimab/cilgavimab
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the contribution by the Minister of State at the Department of Health and Social Care on 12 October to the Westminster Hall debate on the Procurement of Evusheld, Official Report, column 107WH, on what date she plans to announce the accelerated timetable for the NICE assessment of Evusheld.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	66027
answer	answer is ministerial correction date of answer 25/10/2022 answer text <p>The National Institute for Health and Care Excellence (NICE) is conducting a Health Technology Evaluation of Evusheld. This is the routine process for new medicines to be evaluated for clinical and cost effectiveness, which will provide recommendations through NICE’s guidance on the use of Evusheld in the National Health Service. The NICE appraisal is in development and publication is expected in spring 2023.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 25/10/2022 14:57:30 answering member 4320 label Biography information for Robert Jenrick previous answer version 25963 answering member constituency Newark answering member printed Robert Jenrick answering member 4320 label Biography information for Robert Jenrick
tabling member	4769 label Biography information for Daisy Cooper